Stockholm August 25, 2021 - Intervacc has stated in the published financial calendar that the report for the first half of 2021 would be made public on September 3, 2021. The report will be made public on August 31, 2021 in accordance with the rules of the Nasdaq First North Growth Market.
For more information please contact:
Andreas Andersson, CEO
Phone: +46 (0)8 120 10 601, Cell: +46 (0)73 335 99 70
E-mail: andreas.andersson@intervacc.com
The information was submitted for publication, through the agency of the contact person set out above on August 25, 2021, 14.45 CET.
About Intervacc
Intervacc AB is a Swedish company within animal health developing safe, effective vaccines for animals. The Company's vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the NASDAQ First North Growth Market since April 2017 with Eminova Fondkommission AB, adviser@eminova.se, +46 (0)8-684 211 10 as Certified Adviser.
Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: adviser@eminova.se, Phone: +46 (0)8 - 684 211 10
https://news.cision.com/intervacc/r/intervacc-brings-forward-the-report-for-the-first-half-of-2021-to-august-31--2021,c3403069
https://mb.cision.com/Main/4632/3403069/1458897.pdf
https://news.cision.com/intervacc/i/a-new-generation-of-vaccines-within-animal-health,c2947443
(c) 2021 Cision. All rights reserved., source Press Releases - English
INTERVACC AB 
